Feedback
Carisoprodol Urine with Reflex to Quantitation
2012278
Ordering Recommendation

Useful for general screening in contexts of compliance and/or abuse. A screen with reflex testing is the preferred method for ruling out carisoprodol and/or meprobamate exposure. For follow-up testing of a presumptive result, Carisoprodol and Meprobamate, Urine, Quantitative (2012219) is preferred.

Mnemonic
CARIS RFXU
Methodology
QualitativeEnzyme Immunoassay/Quantitative Liquid Chromatography - Tandem Mass Spectrometry
Performed
Sun-Sat
Reported
1-6 days
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
ARUP Consult®
Disease Topics
Specimen Required
Patient Preparation
 
Collect
Random urine. 
Specimen Preparation
Transfer 4 mL urine with no additives or preservatives to an ARUP Standard Transport Tube. (Min: 2 mL) 
Storage/Transport Temperature
Refrigerated. 
Unacceptable Conditions
Breast milk. Pharmaceutical preparation. Specimens exposed to multiple freeze thaw cycles. 
Remarks
 
Stability
Ambient: 10 days; Refrigerated: 10 days; Frozen: 3 weeks 
Reference Interval
Screen cutoff concentration 100 ng/mL
Interpretive Data
The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration at which the screening test can detect a drug or metabolite varies. Specimens for which drugs or drug classes are detected by the screen are reflexed to a second, more specific technology (GC/MS and/or LC-MS/MS). The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.

For medical purposes only; not valid for forensic use.

Compliance Statement B: This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Note
If the specimen screens positive, then Confirmation/Quantitation by GC-MS (ARUP test code 2012219) will be added to confirm result. Additional charges apply.
CPT Code(s)
80307; if positive add 80369 (Alt code: if positive add G0480)
Components
Component Test Code*Component Chart NameLOINC
2012212Screen, Urine Interpretation54247-2
2012279Carisoprodol, Urn, Screen10979-3
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases